Page 6 - Torrent Pharma

Torrent Pharma Q1 net grows marginally by 3% as price erosion in US weighs

The company's revenues also grew in single digits at four per cent, from Rs 2,056 crore in Q1 of FY21 to Rs 2,134 crore in Q1 of FY22

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

These are scheduled drugs (or ones that are under price control) and low priced

Cipla, Dr Reddy's Labs: Tech charts show up to 11% upside in pharma stocks

After hitting a new all-time high of Rs 997 earlier today, the stock of Cipla is all set to rally towards Rs 1,100

Hope to launch diabetic NCE by next financial year: Torrent Pharma's Mehta

We would also look into distribution opportunities to bring some of these products into the market, said Mehta

Torrent Pharma shares rise 6% post March quarter results

HDFC Securities said that Torrent's Q4 results were largely in line with their estimates as strong trends in India and Germany offset weak US

Torrent Pharma's Q4 consolidated net profit up 3 pc at Rs 324 crore

Drug firm Torrent Pharma reported a 3.18 per cent rise in its consolidated net profit to Rs 324 crore for the quarter ended March 31, 2021

Torrent Pharma inks pact with Eli Lilly for Covid drug Baricitinib in India

Under royalty-free, non-exclusive deal, Torrent can make and sell baricitinib in India along with the US firm's other license partners

Nifty outlook & trading ideas by Gaurav Garg of CapitalVia Global Research

Nifty index can witness profit booking only if it breaks level of 14,800

Short-term trend in Nifty bearish, stay stock-specific: Vinay Rajani

The trend of midcap and smallcap stocks has been strong and stock specific bullishness is likely to continue

Weak US outlook in near term, higher costs to weigh on Torrent Pharma

While the stock has corrected, valuations leave little room for upside

Torrent Pharma shares tumble 8% post December quarter results

While the outlook for its key geographies is expected to improve over the medium term, the current valuation largely captures the upside, analysts said

Torrent Pharma Q3 net up by 18% to Rs 297 cr even as US revenues dip

India revenues grew 7% to stand at Rs 930 cr. Company's consolidated total revenue from operations fell marginally by under 1% to Rs 2,003 cr in Q3FY21

Torrent Pharma third quarter net profit up 18% at Rs 297 crore

The firm reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the quarter ended in December.

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Torrent Pharma: Cost controls not enough, recovery in key markets crucial

Chronic and sub-chronic therapies, accounting for 77 per cent of India sales, are outperforming the domestic market, say analysts

Sensex surges 377 pts as financial, FMCG stocks rally; Nifty ends at 11,889

All that happened in the markets today

Torrent Pharma Q2 net up 27% despite dip in US and Brazil revenues

Firm's consolidated total revenue for the quarter, however, fell marginally by 0.7% to stand at Rs 2,023 crore

Torrent Pharma Q2 profit up 27% at Rs 310 cr on robust sales, low expenses

The company had posted a net profit of Rs 244 crore for the corresponding period of the previous fiscal, Torrent Pharmaceuticals said in a filing to BSE

Nifty outlook & stock calls by Anand Rathi: Buy TCS, Torrent Pharma

TCS' stock has provided a breakout from a descending triangle pattern on the daily chart

Nifty may resume downtrend if it breaks below 11,350: HDFC Securities

The recent high of 11,794 would continue to act as strong resistance for the Nifty